ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ruzinurad (SHR 4640) / Jiangsu Hengrui Pharma
NCT04052932: A Study of Evaluating the Efficacy and Safety of SHR4640 in Subjects With Gout

Completed
3
594
RoW
SHR4640 dose1, SHR4640 dose2, Placebo oral tablet, Allopurinol 300 MG
Jiangsu HengRui Medicine Co., Ltd.
Gout
07/21
07/21
NCT04956432: A Multicentre, Randomized, Double-blind, Allopurinol Controlled Study to Evaluate the Efficacy and Safety of SHR4640 in Subjects With Gout

Active, not recruiting
3
780
RoW
SHR4640, Allopurinol
Jiangsu HengRui Medicine Co., Ltd.
Gout
07/24
07/24

Download Options